A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols
- 1 October 2000
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 40 (10) , 1182-1191
- https://doi.org/10.1046/j.1537-2995.2000.40101182.x
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- The incidence/window period model and its use to assess the risk of transfusion-transmitted human immunodeficiency virus and hepatitis C virus infectionTransfusion Medicine Reviews, 1997
- Natural history of liver fibrosis progression in patients with chronic hepatitis CThe Lancet, 1997
- The Risk of Transfusion-Transmitted Viral InfectionsNew England Journal of Medicine, 1996
- The long-term pathological evolution of chronic hepatitis CHepatology, 1996
- The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C virusesHepatology, 1996
- Clinical Outcomes after Transfusion-Associated Hepatitis CNew England Journal of Medicine, 1995
- Non-A, Non-B Post-Transfusion Hepatitis: Looking Back in the Second DecadeAnnals of Internal Medicine, 1993
- Long-Term Mortality after Transfusion-Associated Non-A, Non-B HepatitisNew England Journal of Medicine, 1992
- The Declining Risk of Post-Transfusion Hepatitis C Virus InfectionNew England Journal of Medicine, 1992
- Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitisJournal of Hepatology, 1992